Why the study?
How did the COVID-19 pandemic affect cardiovascular testing volumes in the United States compared to the rest of the world?
How did the COVID-19 pandemic affect cardiovascular testing volumes in the United States compared to the rest of the world?
The early phase of the COVID-19 pandemic caused marked reductions in cardiovascular testing in the U.S., highlighting the need for proactive efforts to maintain access during outbreaks.
Regional testing variability during early COVID-19 signals access risks in outbreaks; leaves open impacts on CV outcomes and mitigation needs.
We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Its licence doesn't allow us to show a copy here.
Hirschfeld et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: